CAT vs REGN · P/E 48, rev $20.54B vs P/E 14, rev $14.34B
Caterpillar Inc (CAT) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Caterpillar Inc (CAT) is a farm & heavy construction machinery company listed on NYSE. It is led by Jim Umpleby.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported CAT revenue for 2026-06-30 was $20.54B. Net income was $3.59B. Revenue was up 18.0% from 2026-03-31 to 2026-06-30. CAT currently screens at market cap $440.29B and trailing P/E 47.7.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
CAT currently screens at market cap $440.29B and trailing P/E 47.7. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the CAT and REGN stock pages for the full models.
Not investment advice.